Literature DB >> 3612817

Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.

C Bode, M S Runge, J B Newell, G R Matsueda, E Haber.   

Abstract

The unidirectional crosslinking agent N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) was used to covalently couple fibrin-specific antibody Fab' to low-molecular-weight urokinase by means of the sulfhydryl groups of the inter-heavy-chain disulfide bonds. At enzymatic activities equal with respect to the substrate pyroglutamyl-glycyl-arginyl-p-nitroanilide-hydrochloride, the Fab'-urokinase conjugate lysed fibrin monomer linked to sepharose with a potency 95 times that of urokinase (which is essentially identical to the potency previously reported for an intact antibody-urokinase conjugate). The Fab'-urokinase conjugate also lysed human thrombi in fresh citrated plasma with a maximal potency 4.4 times that of uncoupled urokinase. These findings indicate that univalent antibody binding is sufficient to enhance fibrinolysis and that the increased potency of antifibrin-urokinase conjugates can also be demonstrated when cross-linked thrombi are used as substrate in the presence of plasma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612817     DOI: 10.1016/s0022-2828(87)80578-3

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

Review 1.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

2.  Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.

Authors:  M S Runge; C Bode; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

4.  Construction and expression of a recombinant antibody-targeted plasminogen activator.

Authors:  J M Schnee; M S Runge; G R Matsueda; N W Hudson; J G Seidman; E Haber; T Quertermous
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 5.  [Antibody mediated thrombolysis. A new therapeutic principle].

Authors:  C Bode; W Kübler
Journal:  Klin Wochenschr       Date:  1989-07-03

Review 6.  New strategies in the development of thrombolytic agents.

Authors:  H R Lijnen; D Collen
Journal:  Blut       Date:  1988-10

Review 7.  Thrombolytic agents in development.

Authors:  M Verstraete; H R Lijnen; D Collen
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

8.  A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.

Authors:  Shingo Hanaoka; Shinji Saijou; Yasuhiro Matsumura
Journal:  Thromb Haemost       Date:  2021-06-15       Impact factor: 6.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.